Cryolife Inc (CRY) Director C Elkins Ronald Sells 5,000 Shares of Stock

Share on StockTwits

Cryolife Inc (NYSE:CRY) Director C Elkins Ronald sold 5,000 shares of Cryolife stock in a transaction on Wednesday, September 5th. The shares were sold at an average price of $34.53, for a total transaction of $172,650.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

C Elkins Ronald also recently made the following trade(s):

  • On Friday, August 10th, C Elkins Ronald sold 1,154 shares of Cryolife stock. The shares were sold at an average price of $33.27, for a total transaction of $38,393.58.
  • On Thursday, June 14th, C Elkins Ronald sold 5,000 shares of Cryolife stock. The shares were sold at an average price of $28.89, for a total transaction of $144,450.00.

Shares of Cryolife stock traded down $0.05 during trading hours on Friday, reaching $34.50. The company’s stock had a trading volume of 1,659 shares, compared to its average volume of 161,171. Cryolife Inc has a one year low of $16.80 and a one year high of $35.05. The company has a quick ratio of 3.63, a current ratio of 4.97 and a debt-to-equity ratio of 0.80. The company has a market cap of $1.27 billion, a PE ratio of 86.00 and a beta of 0.66.

Cryolife (NYSE:CRY) last posted its earnings results on Monday, August 6th. The medical equipment provider reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.07 by $0.03. Cryolife had a negative net margin of 2.34% and a positive return on equity of 4.28%. The firm had revenue of $68.50 million for the quarter, compared to the consensus estimate of $64.08 million. During the same period in the previous year, the firm posted $0.12 EPS. The business’s quarterly revenue was up 43.2% on a year-over-year basis. sell-side analysts expect that Cryolife Inc will post 0.31 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of CRY. Wells Fargo & Company MN increased its holdings in shares of Cryolife by 12.7% in the 1st quarter. Wells Fargo & Company MN now owns 57,221 shares of the medical equipment provider’s stock worth $1,146,000 after buying an additional 6,451 shares during the last quarter. Victory Capital Management Inc. increased its holdings in shares of Cryolife by 98.4% in the 1st quarter. Victory Capital Management Inc. now owns 12,594 shares of the medical equipment provider’s stock worth $253,000 after buying an additional 6,246 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Cryolife by 0.6% in the 1st quarter. Northern Trust Corp now owns 1,170,905 shares of the medical equipment provider’s stock worth $23,477,000 after buying an additional 6,481 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Cryolife by 2.6% in the 1st quarter. BlackRock Inc. now owns 4,457,776 shares of the medical equipment provider’s stock worth $89,378,000 after buying an additional 113,672 shares during the last quarter. Finally, Thomson Horstmann & Bryant Inc. increased its holdings in shares of Cryolife by 1.8% in the 1st quarter. Thomson Horstmann & Bryant Inc. now owns 345,581 shares of the medical equipment provider’s stock worth $6,928,000 after buying an additional 6,171 shares during the last quarter. Hedge funds and other institutional investors own 68.92% of the company’s stock.

A number of analysts have issued reports on CRY shares. Zacks Investment Research upgraded shares of Cryolife from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a report on Friday, May 11th. Northland Securities reiterated a “buy” rating and issued a $32.00 price target on shares of Cryolife in a report on Tuesday, August 7th. ValuEngine upgraded shares of Cryolife from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 23rd. Finally, Canaccord Genuity lifted their price target on shares of Cryolife from $28.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $32.75.

About Cryolife

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Featured Article: How Do Tariffs Affect Trade Balances?

Insider Buying and Selling by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply